Inflammation News and Research

RSS

Hypertonic solution effective in reducing inflammation

Research carried out at The University of Manchester has found further evidence that a simple solution, which is already used in IV drips, is an effective treatment for reducing inflammation.

From The University of Manchester 21 Sep 2012

High uric acid precursor of obesity, metabolic syndrome

The relationship between uric acid and early cardiometabolic risk may precede obesity and the metabolic syndrome, show study findings.

20 Sep 2012

Close monitoring could give early warning of MS disease course

Patients with multiple sclerosis who have breakthrough disease activity early in the course of treatment with interferon beta-1a are at high risk for severe worsening and poor long-term outcomes, research shows.

20 Sep 2012

Gum disease bacteria linked to pancreatic cancer risk

People with high levels of antibodies to bacteria linked to periodontal disease have an increased risk for pancreatic cancer, while the risk is reduced in those with increased antibodies to oral commensal bacteria, say researchers.

20 Sep 2012

GSK3 inhibition protects against gum disease

Treatment with the cell-permeable glycogen synthase kinase -3β-specific enzyme inhibitor SB216763 successfully suppresses alveolar bone loss in mice infected with the main periodontal pathogen, Porphyromonas gingivalis, report researchers.

20 Sep 2012

PCA inhibits multiple pathways involved in development of diabetic nephropathy

Diabetic nephropathy is one of the most serious complications related to diabetes, often leading to end-stage kidney disease. Purple corn grown in Peru and Chile is a relative of blue corn, which is readily available in the U.S.

20 Sep 2012

Endothelial colony-forming cells show promise against inflammatory bowel disease

New research shows that a special population of stem cells found in cord blood has the innate ability to migrate to the intestine and contribute to the cell population there, suggesting the cells' potential to treat inflammatory bowel disease (IBD).

20 Sep 2012

TECHLAB to utilize Dynex's Gold SmartKit packaging for ELISA product line

Dynex Technologies, Inc. announced today it has finalized a supply agreement with TECHLAB, Inc. (Blacksburg, VA), allowing TECHLAB to utilize Dynex's Gold SmartKit packaging for their ELISA product line.

20 Sep 2012

Obese adults with excess visceral fat, biomarkers of insulin resistance more likely to develop diabetes

Obese adults with excess visceral fat (fat located inside the abdominal cavity, around the body's internal organs) and biomarkers of insulin resistance had an associated increased risk for the development of type 2 diabetes mellitus, while obese individuals with higher amounts of total body fat and subcutaneous fat (underneath the skin) did not have this increased risk, according to a study in the September 19 issue of JAMA, and theme issue on obesity.

20 Sep 2012

Thalidomide effective in treating disabling cough among people with idiopathic pulmonary fibrosis

In the first clinical trial to demonstrate an effective treatment for constant, disabling cough among people with idiopathic pulmonary fibrosis (IPF), researchers at the Johns Hopkins University School of Medicine found that taking thalidomide significantly reduced the cough and improved quality of life.

18 Sep 2012

Researchers to probe causes, treatments of toxic reactions in blood plasma

In the largest undertaking of its kind, scientists at four leading U.S. research institutions are embarking upon a five-year National Institutes of Health (NIH)-funded study to make blood transfusions safer and more effective by uncovering the exact causes of hemoglobin toxicity.

18 Sep 2012

Anthera to initiate blisibimod Phase 3 program for systemic lupus erythematosus

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today provided an update on regulatory discussions for the global development of blisibimod.

17 Sep 2012

Alzheimer's pathology might be increased in patients after surgery and anesthesia

A syndrome called "post-operative cognitive decline" has been coined to refer to the commonly reported loss of cognitive abilities, usually in older adults, in the days to weeks after surgery. In fact, some patients time the onset of their Alzheimer's disease symptoms from a surgical procedure.

15 Sep 2012

UMDNJ, Proteonomix to conduct UMK-121 Phase 1 trial in end-stage liver disease

Proteonomix, Inc., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced it has entered into an agreement with Piscataway, N.J.-based University of Medicine and Dentistry of New Jersey (UMDNJ) to conducted a Phase 1 clinical trial with its proprietary, patent-pending mobilization technology UMK-121 in patients with end-stage liver disease (ESLD).

15 Sep 2012

Potentially worrisome weight gains following tonsillectomy occur mostly in children under 6

Potentially worrisome weight gains following tonsillectomy occur mostly in children under the age of 6, not in older children, a study by Johns Hopkins experts in otolaryngology- head and neck surgery shows.

13 Sep 2012

Angiopoietin-like protein 2 level linked to incident diabetes

Elevated angiopoietin-like protein 2 levels are associated with the development of Type 2 diabetes, show findings from a Japanese study.

12 Sep 2012

Daily low-dose inhaled corticosteroids do not benefit asthmatics

For two decades, asthma treatment for millions of people with a milder form of the disease has consisted of daily inhaled steroid medicine to reduce inflammation. Now, a new study has found that asthmatics who take the low-dose medication as a daily routine do no better than those who turn to their inhalers only when they have symptoms.

12 Sep 2012

Blocking GSK3b enzyme can prevent bacterial-induced periodontal bone loss

A University of Louisville scientist has found a way to prevent inflammation and bone loss surrounding the teeth by blocking a natural signaling pathway of the enzyme GSK3b, which plays an important role in directing the immune response.

12 Sep 2012

KRAS gene mutation recruits second player to trigger pancreatic cancer

More than a cancer-causing gene is needed to trigger pancreatic cancer, a study led by Mayo Clinic has found. A second factor creates a "perfect storm" that allows tumors to form, the researchers say. The study, published in the Sept. 10 issue of Cancer Cell, overturns the current belief that a mutation in the KRAS oncogene is enough to initiate pancreatic cancer and unrestrained cell growth.

11 Sep 2012

Phase III data for Suvorexant, an investigational insomnia medicine, announced

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. The new data are from one of the longest, continuously-dosed, placebo-controlled trials of a sleep medication ever conducted.

10 Sep 2012